Related Experiment Video
Updated: Jun 29, 2026
Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice
Published on: May 13, 2019
Paeoniflorin attenuates cuproptosis and ameliorates left ventricular remodeling after AMI in hypobaric hypoxia
Xin Fang1, Yaoxuan Ji2, Shuang Li1
1Department of Radiology, West China Hospital, Sichuan University, No. 37 Guoxue Road, Chengdu, 610041, China.
Abstract:
This study investigates the cardioprotective effects of Paeoniflorin (PF) on left ventricular remodeling following acute myocardial infarction (AMI) under conditions of hypobaric hypoxia. Left ventricular remodeling post-AMI plays a pivotal role in exacerbating heart failure, especially at high altitudes. Using a rat model of AMI, the study aimed to evaluate the cardioprotective potential of PF under hypobaric hypoxia. Ninety male rats were divided into four groups: sham-operated controls under normoxia/hypobaria, an AMI model group, and a PF treatment group. PF was administered for 4 weeks after AMI induction. Left ventricular function was assessed using cardiac magnetic resonance imaging. Biochemical assays of cuproptosis, oxidative stress, apoptosis, inflammation, and fibrosis were performed. Results demonstrated PF significantly improved left ventricular function and remodeling after AMI under hypobaric hypoxia. Mechanistically, PF decreased FDX1/DLAT expression and serum copper while increasing pyruvate. It also attenuated apoptosis, inflammation, and fibrosis by modulating Bcl-2, Bax, NLRP3, and oxidative stress markers. Thus, PF exhibits therapeutic potential for left ventricular remodeling post-AMI at high altitude by inhibiting cuproptosis, inflammation, apoptosis and fibrosis. Further studies are warranted to optimize dosage and duration and elucidate PF's mechanisms of action.
Insights
Paeoniflorin (PF) protects against heart damage after acute myocardial infarction (AMI) in high-altitude conditions. This study shows PF improves heart function by reducing cell death, inflammation, and scarring, offering potential therapeutic benefits.
Area of Science:
- Cardiovascular Research
- Altitude Physiology
- Pharmacology
Background:
- Left ventricular remodeling post-acute myocardial infarction (AMI) worsens heart failure, particularly at high altitudes.
- Hypobaric hypoxia presents unique challenges for cardiac recovery after AMI.
- Paeoniflorin (PF) is a potential therapeutic agent for cardiovascular conditions.
Purpose of the Study:
- To investigate the cardioprotective effects of Paeoniflorin (PF) on left ventricular remodeling in a rat model of AMI under hypobaric hypoxia.
- To evaluate the impact of PF on cardiac function and pathological changes following AMI at high altitude.
- To elucidate the underlying mechanisms of PF's cardioprotective action, including its effects on cuproptosis, oxidative stress, apoptosis, inflammation, and fibrosis.
Main Methods:
- Establishment of an AMI rat model under hypobaric hypoxia.
- Administration of Paeoniflorin (PF) for 4 weeks post-AMI.
- Assessment of left ventricular function using cardiac magnetic resonance imaging.
- Biochemical analysis of cuproptosis markers (FDX1/DLAT, serum copper, pyruvate), oxidative stress, apoptosis (Bcl-2, Bax), inflammation (NLRP3), and fibrosis.
Main Results:
- PF significantly improved left ventricular function and attenuated remodeling in rats with AMI under hypobaric hypoxia.
- PF treatment reduced FDX1/DLAT expression and serum copper levels, while increasing pyruvate.
- PF effectively mitigated apoptosis, inflammation, and fibrosis by modulating key molecular markers.
Conclusions:
- Paeoniflorin (PF) demonstrates significant therapeutic potential for managing left ventricular remodeling after AMI at high altitudes.
- PF exerts its cardioprotective effects by inhibiting cuproptosis, inflammation, apoptosis, and fibrosis.
- Further research is needed to optimize PF dosage and duration and fully understand its mechanisms of action in hypobaric hypoxia conditions.
Related Concept Videos
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...